Circulating progenitor cell release and functional characterization after topotecan plus G-CSF and erythropoietin in small cell lung cancer patients.

  • Authors:
    • S Ferrari
    • M Danova
    • C Porta
    • G Comolli
    • S Brugnatelli
    • P Pugliese
    • A Riccardi
    • E Ascari
  • View Affiliations

  • Published online on: October 1, 1999     https://doi.org/10.3892/ijo.15.4.811
  • Pages: 811-816
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Topotecan is a new antineoplastic agent active in ovarian cancer, with promising activity in small cell lung cancer and predictable toxicity. As a part of our ongoing attempt to optimize the use of disease-specific drugs as circulating progenitor cell (CPC) priming in solid tumors, we have evaluated the effects on CPC release of single-agent Topotecan followed by granulocyte colony-stimulating factor (G-CSF) + human recombinant erythropoietin (rhEPO), together with the cell cycle status of the collected CD34+ cells. Ten pretreated patients with small cell lung cancer received Topotecan (1 mg/m2, i.v. for 5 consecutive days) followed by G-CSF (5 microg/kg/day, s.c.) + rhEPO (10,000 I.U. daily, s.c.), starting 24 h after Topotecan. The combination was well tolerated and no relevant side-effects were recorded. On day +10 (range +9 to +11) after the last dose of Topotecan, the median WBC count and the CD34+ cell peak were 8.2 x 10(3) microl (range 4.9-13.9) and 55 microl (range 28-75), respectively. Using flow cytometry, a detailed cell cycle analysis was performed on these CD34+ cells. The cell cycle distribution was determined by DNA content coupled with bromodeoxyuridine incorporation analysis. Apoptosis was evaluated by quantitating DNA strand breaks. The percentage of CD34+ cells in active S-phase was 10.2+/-5%, while early apoptotic CD34+ cells were detected in a low percentage (5.5+/-3%). Topotecan followed by G-CSF + rhEPO mobilizes CPCs effectively. This sequence exerts a stimulation on CD34+ cell cycle with a protective effect from chemotherapy-induced apoptosis. Taken together, these data could be of value for the incorporation of Topotecan, as well as of the combination of G-CSF and rhEPO, into high-dose chemotherapy programs with CPC support.

Related Articles

Journal Cover

Oct 1999
Volume 15 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ferrari S, Danova M, Porta C, Comolli G, Brugnatelli S, Pugliese P, Riccardi A and Ascari E: Circulating progenitor cell release and functional characterization after topotecan plus G-CSF and erythropoietin in small cell lung cancer patients.. Int J Oncol 15: 811-816, 1999.
APA
Ferrari, S., Danova, M., Porta, C., Comolli, G., Brugnatelli, S., Pugliese, P. ... Ascari, E. (1999). Circulating progenitor cell release and functional characterization after topotecan plus G-CSF and erythropoietin in small cell lung cancer patients.. International Journal of Oncology, 15, 811-816. https://doi.org/10.3892/ijo.15.4.811
MLA
Ferrari, S., Danova, M., Porta, C., Comolli, G., Brugnatelli, S., Pugliese, P., Riccardi, A., Ascari, E."Circulating progenitor cell release and functional characterization after topotecan plus G-CSF and erythropoietin in small cell lung cancer patients.". International Journal of Oncology 15.4 (1999): 811-816.
Chicago
Ferrari, S., Danova, M., Porta, C., Comolli, G., Brugnatelli, S., Pugliese, P., Riccardi, A., Ascari, E."Circulating progenitor cell release and functional characterization after topotecan plus G-CSF and erythropoietin in small cell lung cancer patients.". International Journal of Oncology 15, no. 4 (1999): 811-816. https://doi.org/10.3892/ijo.15.4.811